| Literature DB >> 21042551 |
Morten Schmidt1, Sussie Antonsen, Betina Hansen, Jens Møller, Carsten Thordal, Henrik Toft Sørensen.
Abstract
BACKGROUND: As the population ages, an increasing number of acute medical patients will be older and have comorbidities that may interact with their primary admission condition and worsen their prognosis.Entities:
Keywords: cohort study; comorbidity; epidemiology; hospital admission; internal medicine; prognosis; registries
Year: 2010 PMID: 21042551 PMCID: PMC2964073 DOI: 10.2147/CLEP.S12171
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Characteristics of patients with a first-ever admission to the medical admission unit at Aarhus University Hospital, Nørrebrogade, during 2008
| Patients | ||
|---|---|---|
| n | % | |
| Overall | 3,727 | 100.0 |
| Gender | ||
| Female | 1,997 | 53.6 |
| Male | 1,730 | 46.4 |
| Age group (y) | ||
| 18–64 | 2,045 | 54.9 |
| 65–80 | 886 | 23.8 |
| >80 | 796 | 21.4 |
| Charlson comorbidities | ||
| Myocardial infarction | 263 | 7.1 |
| Congestive heart failure | 358 | 9.6 |
| Peripheral vascular disease | 279 | 7.5 |
| Cerebrovascular disease | 559 | 15.0 |
| Dementia | 86 | 2.3 |
| Chronic pulmonary disease | 661 | 17.7 |
| Connective tissue disease | 195 | 5.2 |
| Ulcer disease | 335 | 9.0 |
| Mild liver disease | 176 | 4.7 |
| Diabetes mellitus | 531 | 14.2 |
| Hemiplegia | 29 | 0.8 |
| Moderate to severe renal disease | 137 | 3.7 |
| Diabetes with end-organ damage | 319 | 8.6 |
| Any tumor | 472 | 12.7 |
| Leukemia | 4 | 0.1 |
| Lymphoma | 26 | 0.7 |
| Moderate to severe liver disease | 59 | 1.6 |
| Metastatic solid tumor | 72 | 1.9 |
| AIDS | 3 | 0.1 |
| Comorbidity level | ||
| Low | 1,624 | 43.6 |
| Moderate | 1,241 | 33.3 |
| High | 862 | 23.1 |
Notes: Any hospital discharge diagnosis recorded in the Danish National Patients Registry between 1977 and the index date;
Three levels of comorbidity were defined based on Charlson index scores of 0 (low), 1–2 (moderate), and 3 or more (high).
Frequency and proportion of primary admission conditions according to major ICD-10 groups
| ICD-10 groups | Disease categories | n | % |
|---|---|---|---|
| A00–B99 | Certain infectious and parasitic diseases | 126 | 3.4 |
| C00–D48 | Neoplasms | 19 | 0.5 |
| D50–D89 | Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | 51 | 1.4 |
| E00–E90 | Endocrine, nutritional, and metabolic diseases | 299 | 8.0 |
| F00–F99 | Mental and behavioral disorders | 265 | 7.1 |
| G00–G99 | Diseases of the nervous system | 80 | 2.1 |
| H00–H59 | Diseases of the eye and adnexa | 3 | 0.1 |
| H60–H95 | Diseases of the ear and mastoid process | 5 | 0.1 |
| I00–I99 | Diseases of the circulatory system | 245 | 6.6 |
| J00–J99 | Diseases of the respiratory system | 575 | 15.4 |
| K00–K93 | Diseases of the digestive system | 76 | 2.0 |
| L00–L99 | Diseases of the skin and subcutaneous tissue | 33 | 0.9 |
| M00–M99 | Diseases of the musculoskeletal system and connective tissue | 117 | 3.1 |
| N00–N99 | Diseases of the genitourinary system | 114 | 3.1 |
| O00–O99 | Pregnancy, childbirth, and the puerperium | – | – |
| P00–P96 | Certain conditions originating in the perinatal period | – | – |
| Q00–Q99 | Congenital malformations, deformations, and chromosomal abnormalities | – | – |
| R00–R99 | Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | 522 | 14.0 |
| S00–T98 | Injury, poisoning, and certain other consequences of external causes | 528 | 14.2 |
| V01–Y98 | External causes of morbidity and mortality | 1 | 0.0 |
| Z00–Z99 | Factors influencing health status and contact with health services | 668 | 17.9 |
Note: Among z-categories, 567 (84.9%) were admitted as “medical observation and evaluation for suspected diseases and conditions” (Z03).
Figure 1Relative frequency of primary admission conditions according to major ICD-10 groups (corresponding disease categories are shown in Table 2).
Cumulative mortality risk after 1, 3, and 6 months, overall and according to gender, age, and comorbidity groups
| Cumulative mortality (%) | ||||||
|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | |||||
| 1 mo | 3 mo | 6 mo | 1 mo | 3 mo | 6 mo | |
| Overall | 5.7 | 9.5 | 12.8 | 3.1 | 5.3 | 7.4 |
| Gender | ||||||
| Female | 5.4 | 9.5 | 12.9 | 2.8 | 5.1 | 7.1 |
| Male | 6.0 | 9.4 | 12.7 | 3.4 | 5.5 | 7.7 |
| Age group (y) | ||||||
| 18–64 | 1.7 | 3.1 | 4.4 | 0.9 | 1.6 | 2.3 |
| 65–80 | 7.3 | 11.6 | 17.2 | 6.8 | 10.7 | 16.1 |
| >80 | 13.9 | 23.4 | 29.4 | 13.2 | 22.3 | 28.4 |
| Comorbidity level | ||||||
| Low | 2.0 | 3.0 | 4.2 | 1.0 | 1.5 | 2.1 |
| Moderate | 6.3 | 10.6 | 14.5 | 4.2 | 7.2 | 10.1 |
| High | 11.7 | 20.1 | 26.5 | 10.8 | 18.6 | 24.8 |
Notes: Adjusted for gender, age as continuous variable, and comorbidity level (2 in each analysis);
Three levels of comorbidity were defined based on Charlson index scores of 0 (low), 1–2 (moderate), and 3 or more (high).
Figure 2Mortality for all patients.
Figure 5Mortality according to comorbidity level. A) Unadjusted; B) adjusted.
Figure 3Mortality according to gender. A) Unadjusted; B) adjusted.
Mortality hazard ratios within gender, age, and comorbidity groups
| Hazard ratios (95% confidence intervals) | ||
|---|---|---|
| Unadjusted | Adjusted | |
| Gender | ||
| Female | 1.00 (reference) | 1.00 (reference) |
| Male | 0.99 (0.82–1.18) | 1.16 (0.97–1.39) |
| Age group (y) | ||
| 18–64 | 1.00 (reference) | 1.00 (reference) |
| 65–80 | 4.16 (3.20–5.39) | 2.77 (2.11–3.64) |
| >80 | 7.76 (6.08–9.90) | 5.25 (4.06–6.80) |
| Comorbidity level | ||
| Low | 1.00 (reference) | 1.00 (reference) |
| Moderate | 3.65 (2.76–4.83) | 2.43 (1.82–3.24) |
| High | 7.15 (5.45–9.37) | 3.87 (2.91–5.15) |
Notes: Adjusted for gender, age as a continuous variable, and comorbidity level (2 in each analysis).
Three levels of comorbidity were defined based on Charlson index scores of 0 (low), 1–2 (moderate), and 3 or more (high).
Mortality hazard ratios stratified on gender, age, and comorbidity groups
| Hazard ratios (95% confidence intervals) | ||
|---|---|---|
| Unadjusted | Adjusted | |
| Female patients | ||
| Age 65–80 | 4.74 (3.20–7.03) | 2.93 (1.95–4.41) |
| Age >80 | 8.73 (6.08–12.53) | 5.26 (3.60–7.68) |
| Moderate comorbidity | 4.38 (2.94–6.51) | 2.79 (1.86–4.21) |
| High comorbidity | 8.98 (6.09–13.25) | 4.74 (3.15–7.13) |
| Male patients | ||
| Age 65–80 | 3.77 (2.65–5.34) | 2.68 (1.86–3.86) |
| Age >80 | 7.56 (5.38–10.63) | 5.35 (3.74–7.65) |
| Moderate comorbidity | 3.02 (2.03–4.47) | 2.11 (1.41–3.16) |
| High comorbidity | 5.61 (3.84–8.20) | 3.11 (2.08–4.65) |
| Patients aged 18–64 y | ||
| Male | 1.18 (0.78–1.80) | 1.12 (0.74–1.71) |
| Moderate comorbidity | 2.12 (1.22–3.67) | 2.10 (1.21–3.65) |
| High comorbidity | 4.65 (2.68–8.09) | 4.62 (2.66–8.03) |
| Patients aged 65–80 y | ||
| Male | 1.16 (0.84–1.59) | 1.09 (0.79–1.50) |
| Moderate comorbidity | 1.59 (0.95–2.68) | 1.58 (0.94–2.66) |
| High comorbidity | 2.79 (1.71–4.56) | 2.76 (1.69–4.52) |
| Patients aged ≥80 y | ||
| Male | 1.27 (0.98–1.66) | 1.24 (0.95–1.61) |
| Moderate comorbidity | 2.19 (1.42–3.37) | 2.20 (1.43–3.39) |
| High comorbidity | 2.89 (1.88–4.43) | 2.85 (1.86–4.37) |
| Patients with low comorbidity | ||
| Male | 1.35 (0.84–2.18) | 1.70 (1.05–2.74) |
| Age 65–80 | 5.38 (2.93–9.85) | 5.55 (3.03–10.18) |
| Age >80 | 9.05 (5.13–15.96) | 9.83 (5.54–17.44) |
| Patients with moderate comorbidity | ||
| Male | 0.94 (0.70–1.26) | 1.24 (0.92–1.68) |
| Age 65–80 | 2.81 (1.81–4.37) | 2.83 (1.82–4.40) |
| Age >80 | 6.22 (4.17–9.28) | 6.54 (4.36–9.81) |
| Patients with high comorbidity | ||
| Male | 0.85 (0.66–1.10) | 0.98 (0.75–1.27) |
| Age 65–80 | 1.70 (1.15–2.51) | 1.69 (1.14–2.51) |
| Age >80 | 2.82 (1.94–4.11) | 2.81 (1.92–4.11) |
Notes: The reference groups (not shown) were female patients, patients aged 18–64 years, and patients with low comorbidity.
The adjustments differed between strata and included only the nonstratifying variable (either gender, age as a continuous variable, or comorbidity level). As an exception for age strata, additional adjustment for age as a continuous variable was made;
Three levels of comorbidity were defined based on Charlson index scores of 0 (low), 1–2 (moderate), and 3 or more (high).